Baidu
map

JACC:单动脉冠脉搭桥预后劣于多动脉搭桥

2019-10-31 不详 MedSci原创

多动脉和单动脉冠脉搭桥(CABG)的收益比较一直存在争议。本研究的目的旨在评估和比较多动脉和单动脉CABG术后的远期生存率、并发症和搭桥的通畅性。本研究共纳入分析了2005-2012年接受CABG治疗的26124名患者,其中3647(14%)名患者接受了多动脉CABG,与多动脉CABG相比,单动脉CABG患者年龄更大(平均68 vs. 61岁; p < 0.001),并发症更多,接受更少的旁

多动脉和单动脉冠脉搭桥(CABG)的收益比较一直存在争议。本研究的目的旨在评估和比较多动脉和单动脉CABG术后的远期生存率、并发症和搭桥的通畅性。

本研究共纳入分析了2005-2012年接受CABG治疗的26124名患者,其中3647(14%)名患者接受了多动脉CABG,与多动脉CABG相比,单动脉CABG患者年龄更大(平均68 vs. 61岁; p < 0.001),并发症更多,接受更少的旁路移植(3.4 vs. 3.6; p < 0.001)。经过基线特征差异调整后,多动脉CABG与更低的10年死亡率相关(15.1% vs. 17.3%; p = 0.01),与更低的十年心梗发生率和再介入率相关。

研究结果显示,约85%接受冠脉搭桥的患者为单动脉搭桥,且与多动脉CABG相关,其远期死亡率、心梗发生率和再介入率明显更高。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1663953, encodeId=66c6166395328, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Sun Jun 28 21:37:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854556, encodeId=ee91185455642, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Jan 20 19:37:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326382, encodeId=b498132638240, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Nov 02 00:37:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552925, encodeId=e34a155292527, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Sat Nov 02 00:37:00 CST 2019, time=2019-11-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1663953, encodeId=66c6166395328, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Sun Jun 28 21:37:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854556, encodeId=ee91185455642, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Jan 20 19:37:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326382, encodeId=b498132638240, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Nov 02 00:37:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552925, encodeId=e34a155292527, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Sat Nov 02 00:37:00 CST 2019, time=2019-11-02, status=1, ipAttribution=)]
    2020-01-20 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1663953, encodeId=66c6166395328, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Sun Jun 28 21:37:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854556, encodeId=ee91185455642, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Jan 20 19:37:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326382, encodeId=b498132638240, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Nov 02 00:37:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552925, encodeId=e34a155292527, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Sat Nov 02 00:37:00 CST 2019, time=2019-11-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1663953, encodeId=66c6166395328, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Sun Jun 28 21:37:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854556, encodeId=ee91185455642, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Jan 20 19:37:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326382, encodeId=b498132638240, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Nov 02 00:37:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552925, encodeId=e34a155292527, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Sat Nov 02 00:37:00 CST 2019, time=2019-11-02, status=1, ipAttribution=)]

相关资讯

“微时代-心纪元 中国冠脉无创功能诊断能力提升项目”新闻发布会成功召开

慢性冠脉综合征(CCS)这一概念在9月刚刚结束的欧洲心脏病学年会被首次提出,2019ESC CCS指南中首先强调了疾病全程管理的概念,冠脉无创功能诊断在全病程管理中的诊断价值日益受到重视。为了进一步推动我国冠心病的管理向全程化、精准化、科学化、规范化发展,提升国内冠脉无创功能诊断的能力,2019年10月12日下午,在北京举办的第三十届长城心脏病学会议(GW-ICC)期间召开了“微时代—心纪元

盘点:JACC十月第5期研究一览

1.新型心源性休克风险分层预测模型DOI: 10.1016/j.jacc.2019.07.077http://www.onlinejacc.org/近期心血管造影与介入学会(SCAI)提出了一个新的5期心源性休克(CS)的风险分层模型。本研究的目的旨在将SCAI提出的新的风险分层方法用于心脏重症病房(CICU)患者。本研究纳入分析了梅奥诊所2007-2015年的CICU患者,并基于患者入院时的

Heart:认知功能损伤会增加冠心病患者死亡风险

本研究的目的旨在评估急性冠脉综合征(ACS)老年患者的精神状态是否与更高的死亡率相关。本研究纳入分析了600例年龄≥75岁的ACS患者,并对患者在入院后48小时内进行了精神状态的评估,其中有172例(29%)患者诊断为认知功能损伤(Cogl),1年后,Cogl患者组有49例(28.6%)患者出现死亡,无Cogl患者组有43例(10.3%)患者出现死亡,Cogl与患者1年死亡率呈明显相关性(HR 2

JACC:高静息心率与2型糖尿病存在共同的遗传基础

高的静息心率(RHR)常常伴有2型糖尿病(T2D)和代谢综合征,提示可能有共同的发病机制。本研究的目的旨在评估静息心率与心脏代谢疾病/T2D的遗传基础。通过英国生物数据库(n=428250)和其他相关T2D临床试验的数据,本研究发现RHR和T2D有明显的遗传相关性((r = 0.22; 95% cl: 0.18-0.26; p = 1.99 × 10-22),RHR与其他6个心脏代谢特性也存在遗传

JACC:PCI术后替卡格雷和双重抗凝治疗的比较

GLOBAL LEADERS临床试验将15991名接受经皮冠脉介入治疗患者随机分成1个月双重抗血小板治疗(DAPT)后接受23个月的替卡格雷治疗和传统的12个月DAPT治疗后12个月阿司匹林治疗组。主要有效终点事件是全因死亡、非致死性心梗、非致死性卒中或紧急靶血管血运再生。本研究结果发现,试验组和传统治疗组患者2年后的主要有效终点事件发生率分别是7.14%和8.41%(RR: 0.85; 95%

JACC:不同抗凝药物对房颤患者骨折风险的影响

长期服用维生素k拮抗剂(VKAs)的老年人更容易患骨质疏松,本研究的目的旨在比较和评估接受VKA治疗和直接口服抗凝剂(DOACs)房颤患者的骨质疏松风险。本研究纳入分析了37350名房颤患者,主要终点事件是髋部骨折、要骨质疏松性骨折、任何骨折、开始骨质疏松药物治疗和一个联合终点。相比于接受VKA治疗的患者,接受DOACs治疗患者的2年骨折风险要更低(3.1%vs3.8%),DOAC与更低的骨折([

Baidu
map
Baidu
map
Baidu
map